Enrollment almost complete for ADP P2 (Proof of Concept) and data Q4 2016. Of course, if they want to get an indication for ADP then yes they will have to go on to a P3 in 2017.
Well, perhaps they would sample many major medical centers, ie a 3-day sample packs given free. Meanwhile the 30day bottle will be mailed/ over night?
Just thinking back...the drug rep's are in training...so that has to be completed, they have to get back to their areas too. ....But need the distribution system to be ready to deliver the drug and that I don't know when that will be. But I am assuming about mid-month as a guess.
Vida...0.85% is less than 1%. do you mean 85%? and could you provide the link to that site? TIA.
don't tell anyone...this is just between me and you...My parking lot spy reported yesterday a town car in the parking lot of Acadia with the plate number
" MRKCEO1 ". 4 suits got out.
Yes could drop lower, note volume decreasing will put us at the whim of the shorts ...some of these newbies will get a little tried and if they see other bio's moving up they will jump ship to the next hot potato.
Type Value Conf.
resist. 39.25 2
resist. 36.06 4
resist. 35.23 2
resist. 33.98 5
resist. 32.47 3
resist. 30.73 2
resist. 29.74 5
resist. 28.38 5
supp 27.05 2
supp 25.69 2
supp 24.52 2
supp 23.63 2
supp 21.76 2
supp 20.89 3
supp 19.23 2
supp 17.32 4
I told you.....Cramer..." Acadia Pharmaceuticals: "People like this thing on a takeover basis. I am not going to recommend any stock on a takeover basis that's speculative. S, I'm going to have to say don't buy."
many biotechs have products and I am fairly sure Cramer still calls them speculative and a MK of 3 Bill is not all the large, lower range of Mid cap if you want to be technical.
He will NEVER recommend a so-called " speculative " stocks which he considers most small biotechs to be. Everyone knows this so I would bet the caller knew Cramer would say NO and perhaps hoping to get in lower or needs to cover at a lower level. At any point ignore it.
NUPLAZIDconnect directly, please call 1-844-737-2223.